Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...
Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...
Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising ...
Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the ...
The concept of skipping axillary lymph node dissection (ALND) in some patients with breast cancer was supported by a European noninferiority trial. Among patients with early-stage, node-negative ...
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...
Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...
In breast cancer patients, radiotherapy may reduce lymphedema (arm swelling) risk compared to surgery after neoadjuvant therapy, offering a less invasive option.
D. Scott Lind, M.D., F.A.C.S.; Barbara L. Smith, M.D., Ph.D., F.A.C.S.; Wiley W. Souba, M.D., Sc.D., F.A.C.S. Before the advent of SLN biopsy, axillary dissection was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results